A former client has sued Mills Oakley and a Victorian law firm alleging they were negligent while advising on a property transaction with his parents that did not go through.
Kingfisher Mobile, which provides mobile services to Telstra customers, has taken the telecommunications giant to court for allegedly breached its contractual obligations when it engaged a new provider to take over from Kingfisher.
The Fair Work Ombudsman has brought proceedings against three United Petroleum-branded outlets in Tasmania and South Australia, alleging they underpaid migrant workers by more than $26,000.
The Star is challenging a finding from the commissioner of taxation that the casino giant owes $5.3 million on payments made to junket operators, arguing the payments were not ‘payments for operating or promoting a junket’.
Apple is facing a new class action on behalf of iPhone 6 and 7 users whose phones were ‘throttled’, or slowed down, due to updates the Silicon Valley company made to its iOS operating system, which were aimed at conserving battery life.
Former Victorian Liberal MP Moira Deeming has brought defamation proceedings against the leader of the state’s Liberal party, John Pesutto.
Sydney-based online broker International Capital Markets is facing a class action by inexperienced investors who allegedly lost $500 million in trading risky contracts for difference.
The state of Queensland is facing two class actions for allegedly failing to place First Nations children who were removed from their families with other community members and to ensure they maintained a connection to their family, community and culture.
ANZ is facing proceedings by a shareholder who wants the bank to turn over documents related to its risk management systems in response to concerns it is increasing loans to fossil fuel companies and failing to properly address climate change risks.
South Korean biosimilars company Samsung Bioepis has sued to invalidate two patents held by a German competitor for a pre-filled syringe to treat age-related eye diseases, as generic drug makers race for a piece of the lucrative eye drug market.